TVRD Share Price Performance
US$7.00
-11.25 (-61.64%)
Price US$7.00
Share PriceUS$7.00
Tvardi Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
TVRD Community Narratives
There are no narratives available yet.
Recent TVRD News & Updates
Tvardi Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.52
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Tvardi Therapeutics, Inc. Competitors
Snowflake Analysis
About TVRD
- Founded
- 2017
- Employees
- 11
- CEO
- WebsiteView website
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -1.1%
- 3 Months: 6.8%
- 1 Year: 15.5%
- Year to Date: 13.8%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 1.8% in the Information Technology sector. In contrast to the last week, the market is actually up 16% over the past year. Earnings are forecast to grow by 16% annually. Market details ›